Suggest a Reference

Evidence

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-i
Posted May 15, 2013

Serial assessment of the edge vascular response (EVR) of a bioresorbable vascular scaffold (BVS) compared to a metallic everolimus-eluting stent (EES).

Credits: PubMed, EuroIntervention. 2013 Apr 30

Read More
Flag this
Did you find this helpful? Thumbs up 0 helpful Thumbs down 0 unhelpful

Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus
Posted May 15, 2013

Objectives: The aim of this study was to investigate the incidence and clinical sequelae of small side branch occlusion (SBO) after Absorb (Abbott Vascular, Santa Clara, California) bioresorbable vascular scaffold (BVS) implantation. An interim report of 435 patients from the spirit first and 2 trials.

Credits: PubMed, JACC: Cardiovascular Interventions

Read More
Flag this
Did you find this helpful? Thumbs up 0 helpful Thumbs down 0 unhelpful

Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments.
Posted May 15, 2013

Background: We sought to analyze the mismatch in vascular compliance after ABSORB implantation and its long-term resolution with bioresorption.

Conclusions: The ABSORB scaffold decreases vascular compliance at the site of scaffold implantation. A compliance mismatch is evident immediately post-implantation and in contrast to metallic stents disappears in the mid-term, likely leading to a normalization of the rheological behavior of the scaffolded segment.

Credits: PubMed, Circ J. 2012;76(7):1616-23

Read More
Flag this
Did you find this helpful? Thumbs up 0 helpful Thumbs down 0 unhelpful

Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives.
Posted May 15, 2013

The scaffold is designed for providing a short-term lumen support (up to 6-12 months) and for thereafter being completely bioresorbed, eliminating the permanent caging typical of the metallic DESA. A randomized trial, comparing ABSORB with the Xience Prime stent, will evaluate the efficacy and safety of this device in a wide population.

Credits: PubMed, Expert Rev Med Devices. 2012 Jul;9(4):327-38

Read More
Flag this
Did you find this helpful? Thumbs up 0 helpful Thumbs down 0 unhelpful

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.